Touting a late-stage trial that highlights the effectiveness of Cubicin in reducing heart valve and blood infections caused by Staph bacteria, Cubist Pharmaceuticals says it will ask the FDA for an accelerated review to expand its use. Cubicin is currently approved to prevent skin infections caused by Staph bacteria.
- read this article from the AP for more